Emerging treatments
Tezepelumab
Tezepelumab is a human monoclonal antibody that binds to human thymic stromal lymphopoietin. Tezepelumab has been shown to demonstrate an improvement in nasal polyp symptoms in patients with combined uncontrolled asthma and nasal polyps in clinical trials.[46] Tezepelumab is currently approved in the US and Europe only for the treatment of severe asthma.
Benralizumab
Benralizumab is a human monoclonal antibody that targets interleukin-5. Benralizumab is currently approved in the US and Europe only as an add-on treatment for eosinophilic asthma. However, it is also in trial stages for chronic rhinosinusitis with nasal polyps (CRSwNP).[47][48] One real-life study involving 17 patients with severe eosinophilic asthma and CRSwNP found benralizumab to be efficacious in treating both comorbidities at once.[49]
Use of this content is subject to our disclaimer